Scancell Holdings, a London-based biopharmaceutical company, announced that its phase 2 Scope trial for its flagship cancer vaccine asset, SCIB1, has surpassed its initial milestone. The trial combines SCIB1 with checkpoint inhibitors to treat advanced melanoma.
According to Scancell Holdings, initial data from 11 patients showed an impressive 82% objective response rate (ORR) to the treatment. This exceeded the trial’s predefined ORR goal of 70%. The company highlighted that no other combination of doublet checkpoint inhibitors has achieved such a high response rate in unresectable metastatic melanoma cases.
The primary objective of the trial was to assess whether the ORR in patients with unresectable metastatic melanoma could be improved when combined with checkpoint inhibitors. Scancell Holdings’ successful results suggest that the combination treatment has the potential to be more effective in treating advanced melanoma than previously thought.
While further research and analysis are required, the promising data from the phase 2 trial provide hope for improved treatment options for patients with advanced melanoma. Scancell Holdings’ achievement may pave the way for the development of more effective cancer immunotherapies in the future.
Sources: Scancell Holdings, Dow Jones
